JOHNSON & JOHNSON (Form: 8-K, Received: 07/24/2023 06:21:48)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

July 24, 2023

Johnson & Johnson

(Exact name of registrant as specified in its charter)


New Jersey	1-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $1.00	JNJ	New York Stock Exchange
0.650% Notes Due May 2024	JNJ24C	New York Stock Exchange
5.50% Notes Due November 2024	JNJ24BP	New York Stock Exchange
1.150% Notes Due November 2028	JNJ28	New York Stock Exchange
1.650% Notes Due May 2035	JNJ35	New York Stock Exchange

Item 8.01 Other Events

The information contained in Exhibit 99.1 is hereby incorporated by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.						Description of Exhibit

99.1						Certain preliminary results for the period ended July 2, 2023

104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Johnson & Johnson

(Registrant)

Date:

July 24, 2023

By:

/s/ Robert J. Decker, Jr.

Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)

Exhibit 99.1

The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the three and six months ended July 3, 2022. Johnson & Johnson has provided certain preliminary results below; however, its closing procedures for the fiscal three and six months ended July 2, 2023 are not yet complete. Johnson & Johnson’s actual results for the fiscal three and six months ended July 2, 2023 remain subject to the completion of management’s final review and Johnson & Johnson’s other closing procedures, or subsequent events, as well as the completion of the review of Johnson & Johnson’s financial statements. Accordingly, you should not place undue reliance on these preliminary results set out below, which may differ from actual results. During the course of the preparation of Johnson & Johnson’s unaudited consolidated financial statements and the notes thereto, additional items that require adjustments to the preliminary results presented below may be identified.

The preliminary financial data of Johnson & Johnson included below has been prepared by, and is the responsibility of, Johnson & Johnson’s management. Johnson & Johnson's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

The preliminary and actual results of Johnson & Johnson provided below do not represent a comprehensive statement of Johnson & Johnson’s financial results and should not be viewed as a substitute for unaudited consolidated financial results prepared in accordance with GAAP. In addition, the preliminary results for the fiscal three and six months ended July 2, 2023 are not necessarily indicative of the results to be achieved in any future period.

OVERALL FINANCIAL RESULTS:


	Q2
($ in Millions, except EPS)	2023 (Preliminary)	2022 (Actual)	% Change
Reported Sales	$25,530	$24,020	6.3%
Net Earnings/(Loss)	$5,144	$4,814	6.9%
EPS (diluted)	$1.96	$1.80	8.9%

REGIONAL SALES RESULTS:


Q2			% Change
($ in Millions)	2023 (Preliminary)	2022 (Actual)	Reported
U.S.	$13,444	$12,197	10.2%
International	12,086	11,823	2.2
Worldwide	$25,530	$24,020	6.3%

Note: values may have been rounded

SEGMENT SALES RESULTS:


Q2			% Change
($ in Millions)	2023 (Preliminary)	2022 (Actual)	Reported
Consumer Health	$4,011	$3,805	5.4%
Pharmaceutical	13,731	13,317	3.1
MedTech	7,788	6,898	12.9
Worldwide	$25,530	$24,020	6.3%

Note: Values may have been rounded


Johnson & Johnson and Subsidiaries
Supplementary Sales Data


(Unaudited; Dollars in Millions)	SECOND QUARTER
				Percent Change
	2023 (Preliminary)		2022 (Actual)	Total
Sales to customers by
geographic area

U.S.	$	13,444	12,197	10.2	%

Europe	5,894		6,085	(3.1)
Western Hemisphere excluding U.S.	1,713		1,536	11.5
Asia-Pacific, Africa	4,479		4,202	6.6
International	12,086		11,823	2.2

Worldwide	$	25,530	24,020	6.3	%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries
Supplementary Sales Data


(Unaudited; Dollars in Millions)	SIX MONTHS
				Percent Change
	2023 (Preliminary)		2022 (Actual)	Total
Sales to customers by
geographic area

U.S.	$	25,961	23,611	10.0	%

Europe	12,226		12,109	1.0
Western Hemisphere excluding U.S.	3,300		3,018	9.3
Asia-Pacific, Africa	8,789		8,708	0.9
International	24,315		23,835	2.0

Worldwide	$	50,276	47,446	6.0	%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries
Supplementary Sales Data


(Unaudited; Dollars in Millions)	SECOND QUARTER					SIX MONTHS
				Percent Change					Percent Change
	2023 (Preliminary)		2022 (Actual)	Total		2023 (Preliminary)		2022 (Actual)	Total
Sales to customers by
segment of business


Consumer Health
U.S.	$	1,787	1,687	6.0	%	$	3,522	3,244	8.6	%
International	2,224		2,118	5.0		4,341		4,147	4.7
	4,011		3,805	5.4		7,863		7,391	6.4


Pharmaceutical (1)
U.S.	7,818		7,159	9.2		14,841		13,791	7.6
International	5,913		6,158	(4.0)		12,303		12,395	(0.7)
	13,731		13,317	3.1		27,144		26,186	3.7


Pharmaceutical excluding COVID-19 Vaccine (1)
U.S.	7,818		7,114	9.9		14,841		13,671	8.6
International	5,628		5,659	(0.5)		11,271		11,514	(2.1)
	13,446		12,773	5.3		26,112		25,185	3.7


MedTech
U.S.	3,839		3,351	14.6		7,598		6,576	15.5
International	3,949		3,547	11.3		7,671		7,293	5.2
	7,788		6,898	12.9		15,269		13,869	10.1


U.S.	13,444		12,197	10.2		25,961		23,611	10.0
International	12,086		11,823	2.2		24,315		23,835	2.0
Worldwide	25,530		24,020	6.3		50,276		47,446	6.0


U.S.	13,444		12,152	10.6		25,961		23,491	10.5
International	11,801		11,324	4.2		23,283		22,954	1.4
Worldwide excluding COVID-19 Vaccine (1)	$	25,245	23,476	7.5	%	$	49,244	46,445	6.0	%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales reconciliation schedules.


Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings


(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2023 (Preliminary)				2022 (Actual)				Percent Increase (Decrease)
	Amount			Percent to Sales	Amount			Percent to Sales
Sales to customers	$	25,530		100.0	$	24,020		100.0	6.3
Cost of products sold	8,212			32.2	7,919			33.0	3.7
Gross Profit	17,318			67.8	16,101			67.0	7.6
Selling, marketing and administrative expenses	6,665			26.1	6,226			25.9	7.1
Research and development expense	3,829			15.0	3,703			15.4	3.4
Interest (income) expense, net	(23)			(0.1)	(26)			(0.1)
Other (income) expense, net*	(60)			(0.2)	273			1.1
Restructuring	145			0.5	85			0.4
Earnings before provision for taxes on income	6,762			26.5	5,840			24.3	15.8
Provision for taxes on income	1,618			6.4	1,026			4.3	57.7
Net earnings	$	5,144		20.1	$	4,814		20.0	6.9

Net earnings per share (Diluted)	$	1.96			$	1.80			8.9

Average shares outstanding (Diluted)	2,625.7				2,667.9

Effective tax rate	23.9		%		17.6		%

* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.


Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings


(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2023 (Preliminary)				2022 (Actual)				Percent Increase (Decrease)
	Amount			Percent to Sales	Amount			Percent to Sales
Sales to customers	$	50,276		100.0	$	47,446		100.0	6.0
Cost of products sold	16,607			33.0	15,517			32.7	7.0
Gross Profit	33,669			67.0	31,929			67.3	5.4
Selling, marketing and administrative expenses	12,803			25.5	12,164			25.6	5.3
Research and development expense	7,392			14.7	7,165			15.1	3.2
In-process research and development	49			0.1	610			1.3
Interest (income) expense, net	(43)			(0.1)	(38)			(0.1)
Other (income) expense, net*	7,168			14.3	171			0.4
Restructuring	275			0.5	155			0.3
Earnings before provision for taxes on income	6,025			12.0	11,702			24.7	(48.5)
Provision for taxes on income	949			1.9	1,739			3.7	(45.4)
Net earnings	$	5,076		10.1	$	9,963		21.0	(49.1)

Net earnings per share (Diluted)	$	1.93			$	3.73			(48.3)

Average shares outstanding (Diluted)	2,630.7				2,669.2

Effective tax rate	15.8		%		14.9		%

* Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.

Johnson & Johnson

Segment Sales

(Dollars in Millions)


	SECOND QUARTER					SIX MONTHS
				% Change					% Change
	2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported
CONSUMER HEALTH SEGMENT (1)

OTC
US	$	712	663	7.5	%	$	1,457	1,333	9.3	%
Intl	947		818	15.7		1,844		1,609	14.6
WW	1,659		1,482	12.0		3,301		2,943	12.2

SKIN HEALTH / BEAUTY
US	650		629	3.4		1,267		1,173	8.0
Intl	498		497	0.3		991		965	2.7
WW	1,148		1,126	2.0		2,258		2,138	5.6

ORAL CARE
US	173		170	1.7		332		313	6.2
Intl	225		224	0.3		427		447	(4.7)
WW	398		394	0.9		759		760	(0.2)

BABY CARE
US	99		88	12.5		195		173	12.7
Intl	261		287	(9.1)		524		557	(6.0)
WW	360		375	(4.0)		719		730	(1.6)

WOMEN'S HEALTH
US	4		3	(2.1)		7		7	(0.1)
Intl	235		228	3.5		449		452	(0.7)
WW	238		230	3.4		455		458	(0.6)

WOUND CARE / OTHER
US	149		133	12.3		264		245	7.9
Intl	58		65	(10.3)		107		117	(8.4)
WW	207		197	4.9		371		361	2.6

TOTAL CONSUMER HEALTH
US	1,787		1,687	6.0		3,522		3,244	8.6
Intl	2,224		2,118	5.0		4,341		4,147	4.7
WW	$	4,011	3,805	5.4	%	$	7,863	7,391	6.4	%

See footnotes at end of schedule

Johnson & Johnson

Segment Sales

(Dollars in Millions)


		SECOND QUARTER					SIX MONTHS
					% Change					% Change
		2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported
PHARMACEUTICAL SEGMENT (1) (2)

IMMUNOLOGY
US		$	2,865	2,853	0.4	%	$	5,313	5,354	(0.8)	%
Intl		1,631		1,559	4.7		3,295		3,176	3.8
WW		4,496		4,411	1.9		8,608		8,530	0.9
	REMICADE
	US	277		391	(29.3)		553		749	(26.2)
	US Exports (3)	33		44	(24.9)		74		124	(40.3)
	Intl	152		212	(28.2)		322		437	(26.2)
	WW	462		647	(28.6)		949		1,310	(27.5)
	SIMPONI / SIMPONI ARIA
	US	285		301	(5.1)		556		588	(5.4)
	Intl	244		266	(8.2)		510		549	(7.1)
	WW	529		566	(6.6)		1,066		1,137	(6.2)
	STELARA
	US	1,817		1,731	4.9		3,268		3,110	5.1
	Intl	981		868	13.0		1,974		1,777	11.1
	WW	2,797		2,599	7.6		5,241		4,887	7.2
	TREMFYA
	US	450		382	17.8		856		773	10.7
	Intl	255		214	19.4		489		413	18.4
	WW	706		597	18.3		1,346		1,187	13.4
	OTHER IMMUNOLOGY
	US	4		3	17.8		7		9	(30.2)
	Intl	0		0	—		0		0	—
	WW	4		3	17.8		7		9	(30.2)

INFECTIOUS DISEASES
US		395		415	(4.9)		787		876	(10.2)
Intl		727		901	(19.4)		1,920		1,737	10.5
WW		1,121		1,316	(14.8)		2,707		2,613	3.6
	COVID-19 VACCINE
	US	—		45	*		—		120	*
	Intl	285		499	(43.0)		1,032		881	17.1
	WW	285		544	(47.7)		1,032		1,001	3.0
	EDURANT / rilpivirine
	US	8		9	(9.0)		17		18	(5.3)
	Intl	258		215	19.9		529		454	16.4
	WW	266		225	18.6		546		473	15.6
	PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
	US	382		355	7.6		760		724	5.0
	Intl	109		110	(0.2)		208		242	(13.9)
	WW	491		464	5.8		968		965	0.3
	OTHER INFECTIOUS DISEASES
	US	5		6	(27.2)		10		14	(30.6)
	Intl	74		77	(3.5)		151		160	(5.6)
	WW	79		83	(5.2)		161		174	(7.6)

See footnotes at end of schedule

Johnson & Johnson

Segment Sales

(Dollars in Millions)


		SECOND QUARTER					SIX MONTHS
					% Change					% Change
		2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported
PHARMACEUTICAL SEGMENT (1) (2) (Continued)

NEUROSCIENCE
US		$	1,029	896	14.9	%	$	2,007	1,739	15.4	%
Intl		764		837	(8.8)		1,590		1,735	(8.4)
WW		1,793		1,734	3.5		3,597		3,475	3.5
	CONCERTA / methylphenidate
	US	64		38	68.2		134		73	84.0
	Intl	143		123	16.3		279		245	13.9
	WW	208		161	28.6		414		318	30.0
	INVEGA SUSTENNA / XEPLION / INVEGA
	TRINZA / TREVICTA
	US	721		691	4.3		1,434		1,352	6.0
	Intl	310		362	(14.4)		641		749	(14.5)
	WW	1,031		1,054	(2.1)		2,075		2,102	(1.3)
	SPRAVATO
	US	144		74	93.2		255		135	88.3
	Intl	25		11	*		45		20	*
	WW	169		85	98.2		300		155	93.1
	OTHER NEUROSCIENCE
	US	100		93	9.3		184		179	3.1
	Intl	286		341	(16.4)		625		721	(13.4)
	WW	386		433	(10.9)		809		900	(10.1)

ONCOLOGY
US		2,069		1,679	23.2		3,958		3,261	21.4
Intl		2,329		2,362	(1.4)		4,552		4,731	(3.8)
WW		4,398		4,042	8.8		8,510		7,992	6.5
	CARVYKTI
	US	114		24	*		184		24	*
	Intl	3		—	*		5		—	*
	WW	117		24	*		189		24	*
	DARZALEX
	US	1,322		1,021	29.5		2,513		1,974	27.3
	Intl	1,110		965	15.0		2,182		1,868	16.8
	WW	2,431		1,986	22.4		4,695		3,842	22.2
	ERLEADA
	US	241		233	3.6		490		439	11.8
	Intl	326		218	49.7		619		412	50.3
	WW	567		450	25.9		1,109		850	30.4
	IMBRUVICA
	US	262		349	(24.9)		532		719	(26.0)
	Intl	579		620	(6.7)		1,136		1,288	(11.8)
	WW	841		970	(13.2)		1,668		2,008	(16.9)
	ZYTIGA / abiraterone acetate
	US	9		19	(55.2)		25		38	(34.7)
	Intl	218		486	(55.1)		447		1,006	(55.6)
	WW	227		505	(55.1)		472		1,044	(54.8)
	OTHER ONCOLOGY
	US	122		33	*		214		67	*
	Intl	92		72	27.8		162		156	3.6
	WW	214		106	*		376		224	68.0

See footnotes at end of schedule

Johnson & Johnson

Segment Sales

(Dollars in Millions)


		SECOND QUARTER					SIX MONTHS
					% Change					% Change
		2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported
PHARMACEUTICAL SEGMENT (1) (2) (Continued)

PULMONARY HYPERTENSION
US		$	684	560	22.0	%	$	1,284	1,132	13.4	%
Intl		289		284	2.0		561		563	(0.4)
WW		972		843	15.3		1,844		1,695	8.8
	OPSUMIT
	US	328		265	23.7		601		538	11.6
	Intl	179		173	3.4		346		343	0.9
	WW	507		438	15.7		947		881	7.5
	UPTRAVI
	US	338		272	24.2		642		541	18.7
	Intl	61		56	10.0		119		112	6.6
	WW	399		328	21.8		761		653	16.6
	OTHER PULMONARY HYPERTENSION
	US	18		23	(23.8)		41		53	(23.0)
	Intl	48		55	(10.9)		95		108	(11.7)
	WW	66		78	(14.7)		136		161	(15.5)

CARDIOVASCULAR / METABOLISM / OTHER
US		776		757	2.6		1,491		1,429	4.3
Intl		174		215	(19.0)		386		453	(14.7)
WW		950		972	(2.2)		1,877		1,882	(0.3)
	XARELTO
	US	637		609	4.7		1,215		1,117	8.8
	Intl	—		—	—		—		—	—
	WW	637		609	4.7		1,215		1,117	8.8
	OTHER
	US	138		148	(6.3)		275		312	(11.8)
	Intl	174		215	(19.0)		386		453	(14.7)
	WW	313		363	(13.8)		662		765	(13.5)

TOTAL PHARMACEUTICAL
US		7,818		7,159	9.2		14,841		13,791	7.6
Intl		5,913		6,158	(4.0)		12,303		12,395	(0.7)
WW		$	13,731	13,317	3.1	%	$	27,144	26,186	3.7	%

See footnotes at end of schedule

Johnson & Johnson

Segment Sales

(Dollars in Millions)


		SECOND QUARTER					SIX MONTHS
					% Change					% Change
		2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported
MEDTECH SEGMENT (1) (2)

INTERVENTIONAL SOLUTIONS
US		$	908	525	73.1	%	$	1,771	1,019	73.8	%
Intl		712		525	35.7		1,352		1,123	20.5
WW		1,620		1,049	54.4		3,123		2,141	45.8

	ELECTROPHYSIOLOGY
	US	609		499	22.0		1,180		969	21.7
	Intl	587		469	25.1		1,109		1,001	10.8
	WW	1,196		968	23.5		2,288		1,970	16.2

	ABIOMED
	US	272		—	*		536		—	*
	Intl	59		—	*		119		—	*
	WW	331		—	*		655		—	*

	OTHER INTERVENTIONAL SOLUTIONS
	US	27		26	4.5		55		51	10.8
	Intl	67		56	20.0		125		121	2.8
	WW	93		81	15.1		180		171	5.1

ORTHOPAEDICS
US		1,388		1,338	3.7		2,751		2,627	4.7
Intl		878		820	7.0		1,759		1,719	2.3
WW		2,265		2,157	5.0		4,510		4,345	3.8

	HIPS
	US	250		240	4.1		491		465	5.6
	Intl	147		148	(0.8)		296		312	(5.1)
	WW	397		388	2.2		787		777	1.3

	KNEES
	US	221		216	2.4		447		417	7.2
	Intl	142		133	6.3		284		271	4.8
	WW	363		349	3.9		731		688	6.3

	TRAUMA
	US	483		464	4.3		974		939	3.7
	Intl	255		232	9.9		522		505	3.2
	WW	739		696	6.1		1,496		1,444	3.6

	SPINE, SPORTS & OTHER
	US	433		418	3.5		839		805	4.1
	Intl	334		306	9.0		657		630	4.2
	WW	766		724	5.8		1,495		1,436	4.2

See footnotes at end of schedule

Johnson & Johnson

Segment Sales

(Dollars in Millions)


		SECOND QUARTER					SIX MONTHS
					% Change					% Change
		2023 (Preliminary)		2022 (Actual)	Reported		2023 (Preliminary)		2022 (Actual)	Reported

MEDTECH SEGMENT (1) (2) (Continued)
SURGERY
US		$	1,015	992	2.2	%	$	1,990	1,913	4.0	%
Intl		1,580		1,458	8.4		3,039		2,971	2.3
WW		2,594		2,450	5.9		5,028		4,884	3.0
	ADVANCED
	US	466		454	2.7		910		871	4.5
	Intl	757		702	7.8		1,430		1,431	0.0
	WW	1,222		1,156	5.8		2,340		2,302	1.7

	GENERAL
	US	548		538	1.9		1,079		1,042	3.6
	Intl	823		756	8.9		1,608		1,540	4.5
	WW	1,372		1,294	6.0		2,688		2,582	4.1

VISION
US		529		496	6.6		1,087		1,017	6.9
Intl		778		745	4.6		1,521		1,481	2.7
WW		1,308		1,241	5.4		2,608		2,498	4.4

	CONTACT LENSES / OTHER
	US	409		374	9.1		853		774	10.1
	Intl	530		519	2.2		1,039		1,030	0.9
	WW	939		894	5.1		1,892		1,804	4.9
	SURGICAL
	US	120		122	(1.1)		234		243	(3.6)
	Intl	249		225	10.1		482		451	6.7
	WW	369		347	6.2		716		694	3.1

TOTAL MEDTECH
US		3,839		3,351	14.6		7,598		6,576	15.5
Intl		3,949		3,547	11.3		7,671		7,293	5.2
WW		$	7,788	6,898	12.9	%	$	15,269	13,869	10.1	%

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1)Unaudited

(2)Certain prior year amounts have been reclassified to conform to current year product disclosures

(3)Reported as U.S. sales